Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Split the company?
View:
Post by thadeush on Jul 29, 2022 8:56pm

Split the company?

probably premature at this point, but assuming (like we all are) the bladder cancer treatment gets the results we expect, would it be smart for TLT to split the cancer treatment part of the company and the vaccine part? Just thinking out loud, but with laser therapy and cancer treatment and vaccine/virus treatment TLT may be getting a bit confusing for the market. It also might maximize profits as each part has incredible potential on its own. Thoughts? (sorry if this has already been discussed)
Comment by Rumpl3StiltSkin on Jul 29, 2022 10:23pm
If the data on the Covid vax animal models looks solid I espect TLTs money issues will be solved with a PHAC deal. This will be important for the company so they can focus on their cancer efforts, They might even be able to stay independent moving forward.  If this doesn't happen then spinning off just NMIBC, so they can keep the solid tumor indications, might make since.  Who ...more  
Comment by CancerSlayer on Jul 30, 2022 12:53am
  If we are still independent, any split-up makes the most sense imo once/if we obtain regulatory approvals on both the cancer & vaccine or antiviral fronts....two different markets that requires different strategies/management/capital allocation.  Such a split would not only allow for a more focused/targeted approach to help maximize profits, but it also allows for a potential ...more  
Comment by Oilminerdeluxe on Jul 30, 2022 1:58am
So, is the belief that we will have both new cancer data and a vaxx update sometime in August? Would not mind seeing an improvement in the CR numbers. I guess that goes for us all, he he. It would be easier to commit more money for shares if things improve. Odds for it to happen must be good at least.
Comment by ScienceFirst on Jul 30, 2022 10:06am
Feb. 7 news release mentioned Q4 for an update from NML regarding the COVID-19 indication. Q4 start Oct. 1st.
Comment by Oilminerdeluxe on Jul 30, 2022 10:08am
Aha, thanks.
Comment by fredgoodwinson on Jul 30, 2022 11:37am
Yes an exciting vaccine announcement on the 7th of Feb. The timing of the current preclinical trial was contained in the subsequent Financial Statements published on the 29th of April: 'These results have now laid the groundwork for the next phase of the CRA, which is evaluating the Theralase ® COVID-19 vaccine in the ability to prevent animals from contracting COVID-19, when ...more  
Comment by Pandora on Jul 30, 2022 12:33pm
Yes, the words "be completed by 4Q2022'" certainly suggests it could be in September or ??
Comment by CancerSlayer on Jul 30, 2022 10:53pm
  Would be nice if Canada employed a Canadian version of Operation Ward Speed, but for an intranasal option...an option that has yet to be approved & could either be used as a stand-alone vaccine or to boost a previously mRNA-vaccinated individual.  By providing additional tissue-level/mucosal immunity, you significantly increase your chance of fully blocking the Covid/Omicron ...more  
Comment by CancerSlayer on Jul 30, 2022 10:55pm
Warp speed...
Comment by Rumpl3StiltSkin on Jul 31, 2022 9:25am
Slayer, I believe Canada will fast track this, given it's importance. How they do it is the Question.
Comment by Rumpl3StiltSkin on Jul 30, 2022 12:00pm
Ah, Q4... Well, at least we'll know prior to EoY...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250